India, June 2 -- Pasithea Therapeutics Corp. (KTTA), a clinical-stage biotechnology company, announced it has received Orphan Drug Designation for PAS-004 in treatment of Amyotrophic Lateral Sclerosis by the U.S Food and Drug Administration or FDA.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease which affects the nerve cells of the brain and spinal cord.
PAS-004 is a macrocyclic MEK inhibitor in evaluation for the treatment of RASopathies, MAPK pathway-driven tumours and other diseases.
The company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer, and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with s...